Influenza Vaccine Dose and Dementia Outcomes - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Influenza Vaccine Dose and Dementia Outcomes

US claims data compare high- vs standard-dose formulations in patients aged 65 years or more over 3 years of follow-up

  • By

  • Kathryn Wighton

  • April 10, 2026

  • 3 min

Share

Clinical Report: Influenza Vaccine Dose and Dementia Outcomes

Overview

Revise to emphasize that the study provides Class II evidence but does not establish causality.

Background

Influenza vaccination is crucial for older adults, who are at increased risk for severe influenza-related complications. Understanding the impact of vaccine dosage on cognitive outcomes, such as dementia, is important for optimizing preventive strategies in this vulnerable population. This study explores the potential link between high-dose influenza vaccination and reduced risk of Alzheimer dementia.

Data Highlights

GroupIncident Alzheimer Dementia RiskNumber Needed to Treat (NNT)
High-Dose VaccineLower risk185 at month 25
Standard-Dose VaccineHigher riskN/A

Key Findings

  • High-dose influenza vaccine associated with lower Alzheimer dementia risk in older adults.
  • Maximum absolute risk difference was approximately 0.5%, with an NNT of 185 at month 25.
  • Risk ratios ranged from 0.78 to 0.89, indicating consistently lower risk with high-dose vaccination.
  • Women showed a longer-lasting association compared to men.
  • Secondary analyses indicated sustained seasonal high-dose vaccination also reduced dementia risk.
  • Potential misclassification in claims-based data may affect findings.

Clinical Implications

Highlight the necessity for further research to confirm findings and clarify underlying mechanisms.

Conclusion

Reiterate the need for further investigation into the clinical significance of the findings.

Related Resources & Content

  1. Bukhbinder AS, Neurology, 2023 -- Influenza Vaccine Dose and Dementia Outcomes
  2. Bukhbinder AS, Neurology, 2023 -- High-Dose Inactivated Influenza Vaccine Inconsistently Improves Heterologous Antibody Responses in an Older Human Cohort
  3. Bukhbinder AS, Neurology, 2023 -- Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines on Hospitalization and Mortality Rates Based on Frailty Assessment
  4. CDC, MMWR, 2025 -- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices
  5. Age and Ageing, 2025 -- Influenza vaccination and risk of dementia: a systematic review and meta-analysis
  6. The Journal of Infectious Diseases — Immune Responses of Antineuraminidase Antibodies in Elderly Individuals Following Sequential Administration of Advanced Influenza Vaccines: A Randomized Controlled Study
  7. CDC Guidelines for Influenza Vaccination
  8. Efficacy of High-Dose Influenza Vaccine
  9. Influenza vaccination and risk of dementia: a systematic review and meta-analysis | Age and Ageing | Oxford Academic

Original Source(s)

Influenza Vaccine Dose and Dementia Outcomes

  • by Kathryn Wighton

  • April 10, 2026

Related Content

Erratum to “Efficacy of wearable devices for upper and lower limb rehabilitation in stroke patients: A systematic review and meta-analysis of randomized controlled trials”

  • July 15, 2026

Diet-Dementia Link Varies by Biomarkers

Effects varied by which biomarker and diet were measured, and the study stops short of proving diet changes risk.

Top 10 Evidence-Based Essentials in Neurology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice.